KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $5.4 billion.

  • Bristol Myers Squibb's Long-Term Deferred Tax rose 2695.94% to $5.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.4 billion, marking a year-over-year increase of 2695.94%. This contributed to the annual value of $5.4 billion for FY2025, which is 2695.94% up from last year.
  • As of Q4 2025, Bristol Myers Squibb's Long-Term Deferred Tax stood at $5.4 billion, which was up 2695.94% from $5.0 billion recorded in Q3 2025.
  • Bristol Myers Squibb's Long-Term Deferred Tax's 5-year high stood at $5.4 billion during Q4 2025, with a 5-year trough of $650.0 million in Q2 2021.
  • Its 5-year average for Long-Term Deferred Tax is $2.5 billion, with a median of $1.5 billion in 2023.
  • In the last 5 years, Bristol Myers Squibb's Long-Term Deferred Tax plummeted by 4025.74% in 2021 and then skyrocketed by 13837.52% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Long-Term Deferred Tax stood at $1.4 billion in 2021, then decreased by 6.6% to $1.3 billion in 2022, then soared by 105.95% to $2.8 billion in 2023, then soared by 53.03% to $4.2 billion in 2024, then rose by 26.96% to $5.4 billion in 2025.
  • Its Long-Term Deferred Tax was $5.4 billion in Q4 2025, compared to $5.0 billion in Q3 2025 and $4.6 billion in Q2 2025.